688621.SHG Beijing Sun Novo Pharmaceutical Research Co Ltd
- Market cap
- CNY 6.21B
- P/E
- 924.7x
- P/B
- 4.92x
- ROE
- -4.1%
- Dividend yield
- 0.52%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688621.SHG undervalued?
Graham numberThe Graham number of Beijing Sun Novo Pharmaceutical Research Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Sun Novo Pharmaceutical Research Co Ltd fundamental analysis
No fundamental analysis for Beijing Sun Novo Pharmaceutical Research Co Ltd yet.
Beijing Sun Novo Pharmaceutical Research Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; oncology, …
Full company profileBeijing Sun Novo Pharmaceutical Research Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Sun Novo Pharmaceutical Research Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 36.0M | 135M | 234M | 347M | 494M | 677M | 932M | 1.08B | 1.22B | 852M |
| Gross Profit | 14.3M | 57.1M | 107M | 172M | 264M | 375M | 528M | 541M | 1.22B | 419M |
| Operating Income | 1.15M | 23.6M | 55.0M | 82.8M | 123M | 169M | 194M | 178M | 204M | 49.6M |
| EBITDA | 4.22M | 30.5M | 62.5M | 92.9M | 137M | 196M | 228M | 218M | 226M | -83.6M |
| Net Income | 1.98M | 20.7M | 47.4M | 72.5M | 106M | 156M | 185M | 177M | 196M | -48.8M |
| EPS | 0.02 | 0.25 | 0.56 | 0.86 | 1.08 | 1.40 | 1.65 | 1.58 | 1.79 | -0.44 |
| Balance Sheet | ||||||||||
| Total Assets | 110M | 201M | 286M | 385M | 1.24B | 1.46B | 1.86B | 1.99B | 2.28B | 2.26B |
| Total Liabilities | 76.8M | 128M | 167M | 192M | 473M | 555M | 806M | 885M | 1.05B | 1.05B |
| Shareholders' Equity | 34.1M | 75.2M | 117M | 189M | 762M | 897M | 1.04B | 1.10B | 1.22B | 1.20B |
| Cash & Short-term Investments | 5.62M | 31.7M | 76.5M | 109M | 648M | 622M | 721M | 596M | 462M | 465M |
| Total Debt | 24.6M | 4.88M | 15.9M | 23.5M | 207M | 258M | 425M | 412M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 8.01M | 44.1M | 57.0M | 63.0M | 88.3M | 104M | 92.9M | 32.0M | 93.2M | - |
| Capital Expenditure | 21.0M | 16.4M | 25.7M | 27.0M | 85.0M | 104M | 73.0M | 30.5M | 42.4M | 23.5M |
| Free Cash Flow | -12.9M | 27.7M | 31.3M | 36.0M | 3.29M | 91.9K | 19.9M | 1.54M | 50.8M | -127M |
| Ratios | ||||||||||
| ROE | 5.8% | 27.5% | 40.6% | 38.3% | 13.9% | 17.4% | 17.8% | 16.1% | 16.1% | -4.1% |
| ROA | 1.8% | 10.3% | 16.6% | 18.8% | 8.5% | 10.7% | 9.9% | 8.9% | 8.6% | -2.2% |
| Net Profit Margin | 5.5% | 15.4% | 20.3% | 20.9% | 21.4% | 23.1% | 19.8% | 16.5% | 16.1% | -5.7% |
| Debt to Equity | 0.72x | 0.06x | 0.14x | 0.12x | 0.27x | 0.29x | 0.41x | 0.37x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Sun Novo Pharmaceutical Research Co Ltd dividends
- Dividend yield
- 0.52%
- Forward dividend
- 0.19 CNY
- Payout ratio
- 16.5%
- Ex-dividend date
- Jun 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 32.3M | 0.29 | 16.5% |
| 2024 | CNY 38.2M | 0.34 | 21.5% |
| 2023 | CNY 55.5M | 0.50 | 30.0% |
| 2022 | CNY 21.2M | 0.19 | 13.5% |
| 2021 | CNY 1.25M | 0.01 | 1.2% |
| 2020 | CNY 1.07M | 0.01 | 1.5% |
| 2019 | CNY 306K | 0.00 | 0.6% |
| 2018 | 1.06M | 0.01 | 5.1% |
| 2017 | 508K | 0.01 | 25.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 12, 2023.
Who owns Beijing Sun Novo Pharmaceutical Research Co Ltd
- Insiders 37.01%
- Institutions 7.93%
- Public & others 55.07%
- Shares outstanding 112M
- Free float 73.2M
Beijing Sun Novo Pharmaceutical Research Co Ltd company profile
- Company name
- Beijing Sun Novo Pharmaceutical Research Co Ltd
- Ticker
- 688621.SHG
- ISIN
- CNE100005139
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,335
- Fiscal year end
- December
- Address
- Building 7, Beijing, China, 102200
- Phone
- 86 10 6074 8199
- Website
- sun-novo.com
About Beijing Sun Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; oncology, metabolic diseases, respiratory tract drug delivery and topical preparation platforms; polypeptide and other drug molecular design and development platform; genotoxic impurity detection platform; technology platform for slow and controlled release preparations; drug synthesis platform; and synthesis technology platform. It also offers SMO, clinical quality management, data management and statistical analysis, project management, test center, clinical research center, clinical trials, TMFDocument management, quality control, Medical Writing, medical monitoring, and pharmacovigilance services; and registration-related services for chemical drugs, biological products, and medical device products. In addition, the company operates a quantitative pharmacology platform that uses technology in pharmacokinetics, pharmacodynamics, body function, disease mechanism and test process, and other information for quantitative research; and mass spectrometry, immunological analysis, cell biology, and molecular biology platforms that provide biological analysis services for large and small molecular drugs, as well as operates as a Contract Research Organization for Professional Peptide Drug Research and Development. The company offers clinical research technology services to pharmaceutical companies and new drug research institutions. Beijing Sun-Novo Pharmaceutical Research Co., Ltd. was founded in 2009 and is based in Beijing, China.
Beijing Sun Novo Pharmaceutical Research Co Ltd management
10- Mr. Yujing LiuGM & Director · born 1982
- Mr. Zhi Jiao ZhangFinance Director & Director · born 1979
- Mr. Huan LuoDeputy GM & Director · born 1984
- Ms. Li Ping WeiSecretary & Director · born 1989
- Ms. Yan ShaoDeputy General Manager · born 1978
- Mr. Guangtao HaoDeputy GM & Core Technician · born 1980
- Mr. Yuanbo LiDeputy General Manager · born 1979
- Hao ChenAccounting Supervisor
- Ms. Ming Juan WangCore Technical Staff · born 1976
- Mr. Dao Sheng XieCore Technical Staff · born 1985